| Author | Affiliation |
|---|---|
| Ichiro Hirayama, MD | The University of Tokyo Hospital, Department of Acute Medicine, Hongo, Bunkyo-ku, Tokyo, Japan |
| Ryota Inokuchi, MD, PhD | The University of Tokyo Hospital, Department of Acute Medicine, Hongo, Bunkyo-ku, Tokyo, Japan |
| Takahiro Hiruma, MD, PhD | The University of Tokyo Hospital, Department of Acute Medicine, Hongo, Bunkyo-ku, Tokyo, Japan |
| Kent Doi, MD, PhD | The University of Tokyo Hospital, Department of Acute Medicine, Hongo, Bunkyo-ku, Tokyo, Japan |
| Naoto Morimura, MD, PhD | The University of Tokyo Hospital, Department of Acute Medicine, Hongo, Bunkyo-ku, Tokyo, Japan |
CASE PRESENTATION
A 70-year-old Japanese man with untreated depression but no history of trauma had fallen seven days prior to hospitalization. After the incident he developed disturbance of consciousness, and his speech gradually became incoherent due to masseter spasm. His vital signs on admission were as follows: blood pressure 97/53 mmHg; pulse 99 beats per minute; body temperature 37.8 °C; respiratory rate 15 breaths per minute; SpO2, 99% without oxygenation; Glasgow Coma Scale Eye opening 3, Verbal response 3, Motor response 2. Physical examination revealed a back abrasion, stupor, and spasmodic laughter (Image). Blood tests including markers of inflammation and creatinine kinase, urinalysis, cerebrospinal fluid, blood cultures, imaging, and electroencephalography findings were normal. Administration of human tetanus immunoglobulin, tetanus toxoid, and penicillin did not improve the patient’s symptoms. On day two, blood tests were normal; thus, we administrated 5 mg diazepam. After that, we observed remarkable improvement in the patient’s consciousness, trismus, and fever.
DIAGNOSIS
Catatonia is found in 10% of psychiatric inpatients, but malignant catatonia (MC) is rare.1 Catatonia is mainly caused by primary psychiatric, neurologic, metabolic and drug-induced disorders, as well as brain injury.2 Catatonia is most commonly characterized by mutism, stupor, posturing, and hypokinesis.3 Fever and autonomic dysregulation due to MC often lead to fatal consequences,4 with a mortality rate exceeding 50%.5 Evidence suggests that MC represents a disturbance of dopaminergic and gamma-aminobutyric acid receptors,6 as administration of 1 – 2 mg lorazepam typically leads to rapid resolution of symptoms within two hours.7 Such treatment should be used within 24 hours after excluding alternative diagnoses.8 Because diagnosis is often difficult and delayed,9 administration of low-dose benzodiazepines (e.g., five mg diazepam) may be warranted in patients with a history of psychological disorders presenting with MC symptoms.
CPC-EM Capsule
What do we already know about this clinical entity?
Malignant catatonia (MC) often leads to fatal consequences. Administration of low-dose lorazepam typically leads to rapid resolution of symptoms; thus, definite diagnosis is crucial.
What is the major impact of the image?
Because MC resembles tetanus, diagnosis is often difficult and delayed.
How might this improve emergency medicine practice?
Administration of low-dose benzodiazepines may be warranted when patients presenting with MC symptoms have a history of psychological disorders and normal blood, urine, cerebrospinal fluid testing and imaging.
Documented patient informed consent and/or Institutional Review Board approval has been obtained and filed for publication of this case report.
Footnotes
Section Editor: Shadi Lahham, MD, MS
Full text available through open access at http://escholarship.org/uc/uciem_cpcem
Address for Correspondence: Ryota Inokuchi, MD, PhD, The University of Tokyo Hospital, Department of Acute Medicine, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. Email: inokuchir-icu@h.u-tokyo.ac.jp. 2:369 – 370
Submission history: Revision received April 15, 2018; Submitted July 9, 2018; Accepted July 18, 2018
Conflicts of Interest: By the CPC-EM article submission agreement, all authors are required to disclose all affiliations, funding sources and financial or management relationships that could be perceived as potential sources of bias. The authors disclosed none.
REFERENCES
1. Ohi K, Kuwata A, Shimada T, et al. Response to benzodiazepines and the clinical course in malignant catatonia associated with schizophrenia: A case report. Medicine (Baltimore). 2017;96(16):e6566.
2. James LL. Medical aspects of catatonia. Prim Psychiatry. 2009;16:23-6.
3. Wilcox JA, Reid DP. The syndrome of catatonia. Behav Sci (Basel). 2015;5(4):576-88.
4. Park J, Tan J, Krzeminski S, et al. Malignant catatonia warrants early psychiatric-critical care collaborative management: two cases and literature review. Case Rep Crit Care. 2017;2017.
5. Dabrowski M, Parnowski T. Clinical analysis of safety and effectiveness of electroconvulsive therapy. Psychiatr Pol. 2012;46(3):345-60.
6. Lang FU, Lang S, Becker T, et al. Neuroleptic malignant syndrome or catatonia? Trying to solve the catatonic dilemma. Psychopharmacology (Berl). 2015;232(14):1-5.
7. Rosebush PI, Hildebrand AM, Furlong BG, et al. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry. 1990;51(9):357-62.
8. Tuerlings JH, van Waarde JA, Verwey B. A retrospective study of 34 catatonic patients: analysis of clinical care and treatment. Gen Hosp Psychiatry. 2010;32(6):631-5.
9. Van Waarde JA, Tuerlings JH, Verwey B, et al. Electroconvulsive therapy for catatonia: treatment characteristics and outcomes in 27 patients. J ECT. 2010;26(4):248-52.